HER2 Positive Breast CancerPhase 3TROIKANCT03013504
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
A Phase 3 study testing HD201, Herceptin and Docetaxel in people with HER2 Positive Breast Cancer, run by Prestige Biopharma Limited at 15 sites in 13 countries.
Trial summary
In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- HER2 Positive Breast Cancer
- What is being tested?
- HD201, Herceptin and Docetaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 503 participants
- Where
- 15 sitesin 13 countries
- Study dates
- 19 Feb 2018to 13 Jan 2022
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able and willing to give written informed consent.
- Females ≥ 18 years of Age
- Eastern Cooperative Oncology Group (ECOG) performance Status (PS) < 2.
- Known Hormone receptor (oestrogen receptor and progesterone receptor) status.
- HER2 overexpressed as assessed by
- Immunohistochemistry (IHC) or
Show all 23Show fewer
- Fluorescent in situ hybridisation (FISH); FISH positive is defined as FISH amplification Ratio ≥ 2.0 / number of HER2 gene copies per cell >2
- Chromogenetic in stu hybridisation (CISH) positive
- Patients with IHC score 3+ or positive FISH/CISH test
- Patients with an IHC score 2+ must also have a positive FISH/CISH test
- LVEF ≥ 50% or within the normal Level of the Institution, as assessed by echocardiography or MUGA scan.
- Life expectancy > 12 weeks.
- Adequate bone marrow function as evidenced by the following:
- Absolute neutrophils count ≥ 1,500/μL
- Haemoglobin ≥ 9 g/dL
- Platelet count ≥ 100,000/μL Up to 5% Deviation is acceptable.
- Adequate hepatic and renal function as evidenced by the following:
- Creatinine clearance ≥ 60mL/min
- total Bilirubin ≤ 1.5x upper limit of normal (ULN)
- AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN Up to 10% deviation is acceptable.
- Ability to comply with the study protocol.
- Female patients of childbearing potential must have a negative Serum pregnancy test within 7 days prior to first dose of study treatment and agree to use effective contraception (intrauterine device, diaphragm, diaphragm with spermicide or a reliable barrier method, eg condom with spermicide) throughout the study period and 7 months after discontinuation of study drug.
- Non-metastatic, unilateral, newly diagnosed, operable early breast cancer (EBC) of clinical stage II and III including inflammatory breast cancer. Histologically confirmed primary invasive carcinoma of the breast.
Who cannot join
- Patients meeting any of the following criteria must not be enrolled in the study:
- Metastatic (stage IV) with exception of supraclavicular nodes.
- Bilateral breast cancer
- Multicentric breast cancer
- History of any prior invasive breast carcinoma, except for subjects with a past history of ductal carcinoma in situ (DCIS) treated with surgery.
- History of malignant neoplasms within 5 years prior to randomisation, except for curatively treated carcinoma in situ of uterine cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms occurring more than 5 years prior to randomisation are permitted if curatively treated with surgery only).
Show all 26Show fewer
- Previous history of radiation therapy, anti-neoplastic immunotherapy, chemotherapy or anti-neoplastic biotherapy (including prior HER2 directed therapy).
- Major surgery within 2 weeks prior to randomisation
- Serious cardiac illness that would preclude the use of trastuzumab such as:
- history of documented congestive heart failure (CHF) (New York Heart Association, NYHA, class III or greater heart disease)
- LVEF < 50% by echocardiography or MUGA scan
- angina pectoris requiring anti-anginal medication
- evidence of transmural infarction on electrocardiogram (ECG)
- uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg)
- clinically significant valvular heart disease
- high-risk uncontrolled arrhythmias.
- Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary oxygen therapy.
- Known history of active hepatitis B virus (HBV) and active hepatitis C virus (HCV) infection.
- Known HIV infection by patient declaration.
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
- Known hypersensitivity to the IMPs, non-IMPs or any of the ingredients or excipients of the IMPs or non-IMPs.
- Known hypersensitivity to murine proteins.
- Pre-existing peripheral sensory or motor neuropathy ≥ grade 2 (as defined by NCI-CTCAE v4.03).
- Lactating or pregnant woman. A pregnancy test is required for all women of childbearing potential including women who had menopause onset within 2 years prior to randomisation. Women of childbearing potential must agree to use contraceptive methods during the study and for 7 months after the last dose of IMP.
- Participation in any clinical study or having taken any investigational therapy during the 1-month period immediately preceding administration of the first dose.
- Patients unwilling to follow the study requirements.
Trial locations and contacts
15 sites in 13 countries.
15 sites in 13 countries
Hungary2 sites
National Institute of Oncology
Budapest, 1122
University of Debrecen
Debrecen, 4032
Malaysia2 sites
Beacon International Specialist Centre
Kuala Lumpur, 46050
Hospital Kuala Lumpur
Kuala Lumpur, 50586
Ukraine1 site
GI "V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine "
Kharkiv, 61018
About this study
Official title: A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients with HER2+ Early Breast Cancer
In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
Read the detailed description
This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study. 500 patients with HER2+ early breast cancer (EBC) will be randomised (1:1) to receive either HD201 in combination with chemotherapy (n=250) or Herceptin® in combination with chemotherapy (n=250).
HD201 or Herceptin® will be administered every 3 weeks for 8 cycles(24 weeks). After administration of the final neoadjuvant study drug dose, surgery will be done within 3-8 weeks followed by an adjuvant treatment period for 10 cycles.
Patients completing the 18 cycles of treatment and those discontinuing the study will attend an End of Treatment (EOT) visit 4 weeks (+/- 2 days), after last administration of study medication, followed by a follow-up period of 2 years.
Patients will attend study visits every 3 weeks. At each visit, patients will undergo a complete physical examination, vital signs, weight, performance status, clinical laboratory tests and adverse events (AEs), concomitant medication will be recorded. After the EOT visit patients will be followed every 6 months for an additional 24 months or until death, whichever occurs first, to collect data on cardiac safety and disease status.
Cardiac safety will be assessed by echocardiography or multigated acquisition (MUGA) scan to evaluate the left ventricular ejection fraction (LVEF) (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab (more frequent if necessary)) and by means of a 12-lead ECG (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab).
The primary efficacy endpoint, total pathological complete response (tpCR) will be assessed at the time of surgery after neoadjuvant treatment completion after 24 weeks. tpCR will be assessed both by local and by central reading.
Sampling for pharmacokinetics (PK) analysis (determination of Ctrough values) will be performed in all patients before cycle 5 and cycle 8.
An Independent Data Monitoring Committee will be implemented that reviews accumulating data of the clinical trial with respect to any potential safety issues, study progress and critical efficacy endpoints. The members will be selected on the basis of relevant experience and understanding of clinical research and the issues specific to the therapeutic area, as well as previous data monitoring committee experience.
- Conditions
- HER2 Positive Breast Cancer
- Being tested
- HD201, Herceptin, Docetaxel, Epirubicin, Cyclophosphamide
- Keywords
- randomized, double-blind, parallel group, equivalence, multicentre, phase III, efficacy, safety, pharmacokinetics, HD201, docetaxel, Herceptin, HER2 positive, breast cancer, early breast cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HD201Drug
Also called Trastuzumab
Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
HerceptinDrug
Also called Trastuzumab
Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
DocetaxelDrug
75mg/m2 via i.v. infusion during cycles 1 to 4.
EpirubicinDrug
75 mg/m2 via i.v. infusion during cycles 5-8.
CyclophosphamideDrug
500 mg/m2 via i.v. infusion during cycles 5-8.
| Study group | Role | What they receive |
|---|---|---|
| HD201 in combination with docetaxel | Experimental | 8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
Neoadjuvant chemotherapy:
Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion Receives: Drug: HD201; Drug: Docetaxel; Drug: Epirubicin; Drug: Cyclophosphamide |
| Herceptin® in combination with docetaxel | Active comparator | 8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.
Neoadjuvant chemotherapy:
Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion Receives: Drug: Herceptin; Drug: Docetaxel; Drug: Epirubicin; Drug: Cyclophosphamide |
What is being measured
The primary outcome is the main question the study is designed to answer.
total pathological complete response rate (tpCR)
To compare the total pathological complete response rate (tpCR) in patients treated with HD201 plus chemotherapy to that in patients treated with Herceptin® plus chemotherapy.
Measured: After 24 weeks (end of cycle 8)
Secondary outcomes (10)
total breast pathological complete response rate (bpCR)
To compare total breast pathological complete response rate (bpCR) between the two arms at the time of surgery.
Measured: After 24 weeks (end of cycle 8)
Overall response rate (ORR)
ORR defined as proportion of patients whose best overall response is either complete response (CR) or partial response (PR) at the time of surgery.
Measured: After 24 weeks (end of cycle 8)
Overall Survival (OS)
OS defined as the time from Day 1 of therapy until death from any cause
Measured: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first
Event-free Survival (EFS)
EFS defined as the time from Day 1 of therapy (day of first infusion of medication on study) until progression of disease or death from any cause.
Measured: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Safety and tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events and CTC v4.03
Measured: From baseline through study completion until 18 months or until death, whichever came first
Cardiac dysfunction
Cardiac dysfunction will be monitored by 12-Lead ECG and measurement of the LVEF by echocardiography or MUGA scan
Measured: Within 28 days before start of treatment, before cycle 5,12 and 16 (1 cycle is 3 weeks), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.
Immunogenecity
Incidence of human trastuzumab antibodies
Measured: At baseline (within 28 days before start of treatment), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.
Clearance (Pharmacokinetic)
Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.
Measured: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Area under the curve (AUC, Pharmacokinetic)
Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.
Measured: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Plasma half life (Pharmacokinetic)
Sampling will be performed in all patients to compare the PK through values of HD201 and Herceptin.
Measured: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2017 (estimated)
- Study start19 Feb 2018
- Primary completion19 Apr 2019
- Study completion13 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HER2 Positive Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 503 participants (actual)
Sponsor and investigators
- Lead sponsor
- Prestige Biopharma Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03013504
- Sponsor's protocol ID
- TROIKA
- Acronym
- TROIKA
- Status last verified
- Feb 2023
- First submitted
- 29 Dec 2016
- Last updated
- 6 Nov 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pivot X, Manikhas AG, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Deforce F, Cox DG. Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting. BMC Cancer. 2023 Jan 31;23(1):112. doi: 10.1186/s12885-023-10574-2.
PubMed 36721174Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):698-705. doi: 10.1001/jamaoncol.2021.8171.
PubMed 35238873
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients with HER2+ Early Breast Cancer
- ClinicalTrials.gov ID
- NCT03013504
- Acronym / sponsor ID
- TROIKA / TROIKA
- Conditions
- HER2 Positive Breast Cancer
- Keywords
- randomized, double-blind, parallel group, equivalence, multicentre, phase III, efficacy, safety
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 503 participants (actual)
- Lead sponsor
- Prestige Biopharma LimitedIndustry (pharma, biotech, devices)
- Study start
- 19 Feb 2018 (actual)
- Primary completion
- 19 Apr 2019 (actual)
- Study completion
- 13 Jan 2022 (actual)
- First posted
- 6 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
Detailed description
This is a randomised, double-blind, parallel group, equivalence, multicentre Phase III study. 500 patients with HER2+ early breast cancer (EBC) will be randomised (1:1) to receive either HD201 in combination with chemotherapy (n=250) or Herceptin® in combination with chemotherapy (n=250).
HD201 or Herceptin® will be administered every 3 weeks for 8 cycles(24 weeks). After administration of the final neoadjuvant study drug dose, surgery will be done within 3-8 weeks followed by an adjuvant treatment period for 10 cycles.
Patients completing the 18 cycles of treatment and those discontinuing the study will attend an End of Treatment (EOT) visit 4 weeks (+/- 2 days), after last administration of study medication, followed by a follow-up period of 2 years.
Patients will attend study visits every 3 weeks. At each visit, patients will undergo a complete physical examination, vital signs, weight, performance status, clinical laboratory tests and adverse events (AEs), concomitant medication will be recorded. After the EOT visit patients will be followed every 6 months for an additional 24 months or until death, whichever occurs first, to collect data on cardiac safety and disease status.
Cardiac safety will be assessed by echocardiography or multigated acquisition (MUGA) scan to evaluate the left ventricular ejection fraction (LVEF) (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab (more frequent if necessary)) and by means of a 12-lead ECG (at screening, before cycle 5, before surgery, before cycles 12 and 16, EOT visit, and at 6 and 12 months after the completion of trastuzumab).
The primary efficacy endpoint, total pathological complete response (tpCR) will be assessed at the time of surgery after neoadjuvant treatment completion after 24 weeks. tpCR will be assessed both by local and by central reading.
Sampling for pharmacokinetics (PK) analysis (determination of Ctrough values) will be performed in all patients before cycle 5 and cycle 8.
An Independent Data Monitoring Committee will be implemented that reviews accumulating data of the clinical trial with respect to any potential safety issues, study progress and critical efficacy endpoints. The members will be selected on the basis of relevant experience and understanding of clinical research and the issues specific to the therapeutic area, as well as previous data monitoring committee experience.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HD201 in combination with docetaxel | Experimental | Drug: HD201, Drug: Docetaxel, Drug: Epirubicin, Drug: Cyclophosphamide8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first. Neoadjuvant chemotherapy: Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion |
| Herceptin® in combination with docetaxel | Active comparator | Drug: Herceptin, Drug: Docetaxel, Drug: Epirubicin, Drug: Cyclophosphamide8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first. Neoadjuvant chemotherapy: Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (23 listed)
- Able and willing to give written informed consent.
- Females ≥ 18 years of Age
- Eastern Cooperative Oncology Group (ECOG) performance Status (PS) < 2.
- Known Hormone receptor (oestrogen receptor and progesterone receptor) status.
- HER2 overexpressed as assessed by
Key exclusion criteria (26 listed)
- Metastatic (stage IV) with exception of supraclavicular nodes.
- Bilateral breast cancer
- Multicentric breast cancer
- History of any prior invasive breast carcinoma, except for subjects with a past history of ductal carcinoma in situ (DCIS) treated with surgery.
- History of malignant neoplasms within 5 years prior to randomisation, except for curatively treated carcinoma in situ of uterine cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms occurring more than 5 years prior to randomisation are permitted if curatively treated with surgery only).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HD201Also: TrastuzumabLoading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles. | Drug | HD201 in combination with docetaxel |
| HerceptinAlso: TrastuzumabLoading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles. | Drug | Herceptin® in combination with docetaxel |
| Docetaxel75mg/m2 via i.v. infusion during cycles 1 to 4. | Drug | HD201 in combination with docetaxel, Herceptin® in combination with docetaxel |
| Epirubicin75 mg/m2 via i.v. infusion during cycles 5-8. | Drug | HD201 in combination with docetaxel, Herceptin® in combination with docetaxel |
| Cyclophosphamide500 mg/m2 via i.v. infusion during cycles 5-8. | Drug | HD201 in combination with docetaxel, Herceptin® in combination with docetaxel |
Primary outcome
total pathological complete response rate (tpCR)
Time frame: After 24 weeks (end of cycle 8)
To compare the total pathological complete response rate (tpCR) in patients treated with HD201 plus chemotherapy to that in patients treated with Herceptin® plus chemotherapy.
10 secondary outcomes
total breast pathological complete response rate (bpCR)
Time frame: After 24 weeks (end of cycle 8)
Overall response rate (ORR)
Time frame: After 24 weeks (end of cycle 8)
Overall Survival (OS)
Time frame: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first
Event-free Survival (EFS)
Time frame: From date of randomisation until death from any cause or two years after End of Treatment, whichever comes first
Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)
Time frame: From baseline through study completion until 18 months or until death, whichever came first
Cardiac dysfunction
Time frame: Within 28 days before start of treatment, before cycle 5,12 and 16 (1 cycle is 3 weeks), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.
Immunogenecity
Time frame: At baseline (within 28 days before start of treatment), before surgery (after 24 weeks), at end of treatment (4 weeks from last administration of drug medication) and one year after completion of trastuzumab therapy.
Clearance (Pharmacokinetic)
Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Area under the curve (AUC, Pharmacokinetic)
Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Plasma half life (Pharmacokinetic)
Time frame: Before administration of treatment at Cycles 5 and 8 (1 cycle is 3 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2024.
- Derived from this study: PubMed 36721174Pivot X, Manikhas AG, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Deforce F, Cox DG. Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting. BMC Cancer. 2023 Jan 31;23(1):112. doi: 10.1186/s12885-023-10574-2.
- Derived from this study: PubMed 35238873Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):698-705. doi: 10.1001/jamaoncol.2021.8171.
- Individual participant dataSharing planned: No
Related trials for HER2 Positive Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
RecruitingObservational study
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
HR+/HER2- Early Breast Cancer
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
15 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing HD201, Herceptin and Docetaxel in people with HER2 Positive Breast Cancer, run by Prestige Biopharma Limited at 15 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in Hungary, Malaysia, Belarus, Bulgaria, Estonia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
total pathological complete response rate (tpCR) (time frame: After 24 weeks (end of cycle 8)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03013504, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2024.